Comitas pharmaceutica Iaponica Otsuka (Otsuka) nuper bonum nuntium accepit in aspectibus moderantibus US, FDA probatus anti-cancer compositum novum pharmacum Lo 3 menses in antecessumnsurf (trifluridine / tipiracil, FTD / TPI) aegros tractare adhibetur cum cancro metastatico refractorio colorectali (mCRC), qui non amplius respondet aliis therapiae (chemotherapy et biotherapy).
Lonsurf (explicatio codicis TAS-102) novum antimetabolitis medicamentum compositum est, quod componitur ex anti- nucleoside nuclei tumoris analogi FTD (trifluridine) et thymidine phosphorylase inhibitoris TPI (tipiracil). Inter eos, FTD substituere potest thyminum directe in DNA duplicatum litium per DNA replicationem, quae ducit ad DNA dysfunctionem et impedit synthesim cellulae cancri DNA; TPI potest inhibere thymum phosphorylasi affinis FTD de compositione et degradationem FTD reducere, Tenere sanguinis intentionem FTD.
Lonsurf’s approval was based on positive data from an international, randomized, double-blind phase III study RECOURSE. The study involved 800 patients with previously treated metastatic colorectal cancer (mCRC). In the study, patients were randomized to receive Lonsurf + best supportive therapy (BSC) or placebo + BSC until the condition deteriorated or the side effects became unbearable. The data showed that the overall survival of the Lonsurf treatment group was significantly longer than that of the placebo group (OS: 7.1 months vs 5.3 months), while progression-free survival was also significantly longer (PFS: 2 months vs 1.7 months) , Reached the primary and secondary endpoints of the study. In terms of safety, the most common side effects of the Lonsurf treatment group include anemia, weakness, extreme fatigue, nausea, decreased appetite, diarrhea, vomiting, abdominal pain, and fever.
Antea, Lonsurf auctoritatibus moderantibus Iapones probatus est mense Martio MMXIV; in Europa, Otsuka album applicationis pro Lonsurf ad Unionem Europaeam mense Martio hoc anno submisit, et societas pacta cum suo socio Servio signavit Ob pactum $ 2014 miliones, Servier respondebit pro venditione commerciali de Lonsurf in Europa continenti. .
Cancer colorectalis Global (CRC) curatio mercatus $9.4 miliardis in 2020 perveniet.
Secundum investigationis relationem per mercatum globalis investigationis societatis GBI Investigationis dimissae, in cancro colorectali globali (CRC) mercatus curationis parvum et stabile incrementum in proximo paucis annis (2014-2020) perveniens, 9.4 miliardis dollariorum ab 2020 In Providemus tempus, compositum rate annuum incrementum (CAGR) 1.8% fuit, et numerus mercatus mercatus anno 2013 fuit $ 8.3 miliarda.
Renuntiatio ostendit hoc incrementum maxime accidere in octo nationibus maioribus progressis, inclusis Civitatibus Foederatis, Iaponia, Canada, et quinque nationibus Europaeis (Imperium, Gallia, Germania, Hispania, Italia). In 2013, Civitatibus Foederatis maximam partem cancri colorectalis globalis (CRC) mercatus curationis, rationem 44.1%, Iaponia (14.7%) et Germania (11.9%), et Hispania (4.1%) cum mercatu infimo habuit partiri. Exspectantur hae nationes tardius crescere, Iaponia excepta, quae in rate celeriore crescent (CAGR of 5%).
Renuntiatio ostendit per tempus praesagio, Roche blockbuster medicamentorum Avastin (nomen genericum: bevacizumab, bevacizumab) et Merck (Merck KGaA) pharmacum blockbuster Erbitux (nomen genericum: cetuximab) , Cetuximab) patentes in maioribus mercatis exspirant, promovebit; mercatus acceptio biosimilaris low-cosi, qui incrementum of the global colorectal cancer curatio mercatus erit. Medicamentum chemotherapeuticum Roche Xeloda (Xeloda, nomen genericum: capecitabinum, capecitabinum) medicamenta generica in maioribus mercatis recensita expectatur ut etiam incrementum capiendi cancri globalis colorectalis curationis fori.
Tamen GBI analysta Saurabh Sharma demonstravit quod, etsi patentes Avastin exspirat, medicamentum suum principatum in cancro colorectali globali (CRC) tractandi mercatum servaturum usque ad annum 2020. Saurabh explicavit quod Avastin late in linea prima et secunda usitata est. -line curatio cancri colorectalis, cuiuscumque K-Ras status patientis. Quamvis factor incrementi epidermalis affinis receptor (EGFR) inhibitores venales sunt pro curatione generis K-Ras silvestris similitudinem anorum ; Avastin suum mercatum dominari perget in curatione metastaticae K-Ras generis silvestris et status tumores mutant.
The report points out that Bayer ‘s new oral anti-cancer drug Stivarga (regorafenib) is expected to be one of the biggest drivers of growth in the global colorectal cancer (CRC) treatment market. This is mainly due to the expected clinical treatment expansion of the drug as a maintenance treatment The drug is used for the first-line treatment of metastatic colorectal cancer (mCRC) that has had liver metastases removed. Stivarga is an oral multi-kinase inhibitor currently listed in major markets such as the US, EU, and Japan. In addition, Japan ‘s Dapeng Pharmaceutical ‘s anticancer drug Lonsurf (TAS-102) was approved for third- and fourth-line treatment in Japan in 2014, and Amgen ‘s monoclonal antibody Vectibix (panitumumab) was also approved by the United States. And EU approved for first-line treatment. The market acceptance of these new drugs will promote the growth of the global therapeutic market.
Renuntiatio etiam ostendit in praesagio periodo (2014-2020) plura medicamenta piperina nova expectanda in mercatu ad terram, inter Anticorpum Cyramzae monoclonale Lilium (ramucirumab), Boehringer Ingelheim triplum angiokinasum inhibitoris nintedanib, XBiotech In comitatu monoclonali anticorporis Xilonix. . Sed haec medicamenta intrant maxime competitive lineae secundae et tertiae et tertiae et quartae-lineae curationes et maiorem labem in toto foro non habebunt. Medicamenta notata, quae nunc in foro sunt, perseverent in mercatu dominatu frui, sicut in prioribus et utilioribus curationibus prima linea continentur.
